The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

“You give me butterflies everyday… literally. Happy Birthday PBM,” he captioned his hard launch post. Elaine is a photographer “who enjoys taking environmental portraits,” according to her website.

The Rio-based network of independent pharmacies blames drug industry intermediaries known as pharmacy benefit managers.

"Pittsburgh’s health care ecosystem is both vibrant and challenging, particularly for employers and the employees who make ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Donald Trump will be the 47th President of the U.S. Not since 1892 has a President been elected to two non-consecutive terms, ...

The results of Tuesday's elections changed control of the White House and the Senate but left the key state-level insurance ...

Analyst Allen Lutz of Bank of America Securities reiterated a Sell rating on GoodRx Holdings (GDRX – Research Report), reducing the price ...

Number 5: By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely ...

"This case involves an unlawful price-fixing agreement among several PBMs—orchestrated by the PBM rate aggregator, GoodRx—to ...

There is a tendency to overlook the multiple factors and stakeholders that contributed to the Rx opioid crisis. This includes ...

Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...